Skip to main content

Table 2 Demographic characteristics of intention-to-treat population: MAD study

From: Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults

Parameters

Dose group

Total

(N = 18)

p-value

480 mg

(N = 7)

960 mg

(N = 7)

Placebo

(N = 4)

Age (years)

28.43 ± 6.24

23.00 ± 1.29

31.00 ± 10.49

26.89 ± 6.70

0.0968

Height (cm)

176.80 ± 5.15

175.01 ± 3.46

171.88 ± 6.62

175.01 ± 4.99

0.2509

Weight (kg)

72.96 ± 9.36

70.99 ± 5.42

71.10 ± 10.09

71.78 ± 7.76

0.6339

BMI (kg/m2)

23.30 ± 2.54

23.19 ± 1.83

23.98 ± 1.93

23.41 ± 2.05

0.8855

IBW (kg)

69.13 ± 4.63

67.53 ± 3.10

64.70 ± 5.94

67.52 ± 4.48

0.2509

Alcohol (n, %)

5 (71.4)

2 (28.6)

4 (100)

11 (61.1)

0.0608

Smoking (n, %)

6 (85.7)

1 (14.3)

1 (25.0)

8 (44.4)

0.0235

  1. N number of subject
  2. p-values by Kruskal–Wallis test (age, height, weight, BMI, and IBW)
  3. p-values by Fisher’s exact test (alcohol, smoking)
  4. BMI (kg/m2) = weight (kg)/{height (m)}2
  5. Data presented as N (%) (alcohol, smoking)